Common Stock Beneficial Ownership Percent of Class(2) Series A Preferred Beneficial Ownership Percent of Class(3) Outstanding Series B Preferred Beneficial Ownership Percent of Class(4)
Named Executive Officers and Directors:
Jonathan F. Head, Ph. D. 18,259,413 (5) 7.0 % 500,000 50.0 % 2,892,000 100 %
Andrew A. Kucharchuk 6,333,334 (6) 2.4 % - - - -
Daniel S. Hoverman 60,000 0.0 % - - - -
Charles L. Rice, Jr. 60,000 0.0 % - - - -
Robert N. Holcomb 1,600,002 (7) 0.6 %
Dr. Brian G. Barnett - - - - - -
All executive officers and directors as a group (six persons) 26,312,749 10.0 % 500,000 50.0 % 2,892,000 100 %
Other 5% Stockholders:
Robert L. Elliott, Jr. M.D. 16,926,079 6.5 % 500,000 50.0 % - - %
Manuel Cosme Odabachian(8) 30,579,007 11.7 % - - - - %
Carlos F. Alaman Volnie (9) 30,579,006 11.7 % - - - - %
* Less than 1%.
(1) Unless otherwise indicated, the business address of each person listed is in care of OncBioMune Pharmaceuticals, Inc., 11441 Industriplex Blvd, Suite 190, Baton Rouge LA 70809.
(2) The number and percentage of shares beneficially owned are determined in accordance with Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rule, beneficial ownership includes any shares over which the individual or entity has voting power or investment power and any shares of common stock that the individual has the right to acquire within 60 days of February 21, 2019, through the exercise of any stock option or other right. As of February 21, 2019, 262,659,600 shares of the Company’s common stock were outstanding.
(3) Calculated on the basis of 1,000,000 issued and outstanding shares of Series A preferred stock as of February 21, 2019. Holders of our Series A preferred stock are entitled to 500 votes per share.
(4) Calculated on the basis of 2,892,000 issued and outstanding shares of Series B preferred stock as of February 21, 2019. Holders of our Series B preferred stock are entitled to 100 votes per share.
(5) Includes 1,333,334 shares issuable upon exercise of currently exercisable options.
(6) Includes 1,333,334 shares issuable upon exercise of currently exercisable options.
(7) Includes 333,334 shares held by the wife of Mr.Holcomb.
(8) Shares are owned by Banco Actinver, S.A., in its capacity as Trustee of the Irrevocable Management Trust Agreement Trust No. 2868 and reflects shares beneficially owned by Mr. Cosme whose address is Monte Pelvoux 130, Floor 3, Mexico City, Mexico 11000.
(9) Shares are owned by Banco Actinver, S.A., in its capacity as Trustee of the Irrevocable Management Trust Agreement Trust No. 2868 and reflects shares beneficially owned by Mr. Cosme whose address is Monte Pelvoux 130, Floor 3, Mexico City, Mexico 11000.
DESCRIPTION OF SECURITIES
News 
Market Data 
Discover 
